These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38610078)

  • 1. Janus kinase inhibitors and the changing landscape of vitiligo management: a scoping review.
    Utama A; Wijesinghe R; Thng S
    Int J Dermatol; 2024 Aug; 63(8):1020-1035. PubMed ID: 38610078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
    Wang F; Sun L; Wang S; Davis JM; Matteson EL; Murad MH; Luo F; Vassallo R
    Mayo Clin Proc; 2020 Jul; 95(7):1404-1419. PubMed ID: 32499126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prior herpes zoster occurrence and high-dose corticosteroids increase herpes zoster risk in rheumatoid arthritis patients receiving janus kinase inhibitors in a retrospective and observational study.
    Chen PK; Chang SH; Chen YM; Chen HH; Huang PH; Huang CC; Yeo KJ; Lan JL; Chen DY
    Clin Rheumatol; 2024 Aug; 43(8):2503-2511. PubMed ID: 38954278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Janus kinase inhibitors for atopic dermatitis: a promising treatment modality.
    Cartron AM; Nguyen TH; Roh YS; Kwatra MM; Kwatra SG
    Clin Exp Dermatol; 2021 Jul; 46(5):820-824. PubMed ID: 33484582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cumulative incidence and risk of infection in patients with rheumatoid arthritis treated with janus kinase inhibitors: A systematic review and meta-analysis.
    Ouranos K; Avila DV; Mylona EK; Vassilopoulos A; Vassilopoulos S; Shehadeh F; Mylonakis E
    PLoS One; 2024; 19(7):e0306548. PubMed ID: 39083492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo.
    Kang C
    Drugs; 2024 May; 84(5):579-586. PubMed ID: 38625661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world comparative study of drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis.
    Saito K; Yoshida S; Ebina H; Miyata M; Suzuki E; Kanno T; Sumichika Y; Matsumoto H; Temmoku J; Fujita Y; Matsuoka N; Asano T; Sato S; Migita K
    PLoS One; 2024; 19(7):e0306714. PubMed ID: 38990897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature.
    Loricera J; Tofade T; Prieto-Peña D; Romero-Yuste S; de Miguel E; Riveros-Frutos A; Ferraz-Amaro I; Labrador E; Maiz O; Becerra E; Narváez J; Galíndez-Agirregoikoa E; González-Fernández I; Urruticoechea-Arana A; Ramos-Calvo Á; López-Gutiérrez F; Castañeda S; Unizony S; Blanco R
    Arthritis Res Ther; 2024 Jun; 26(1):116. PubMed ID: 38840219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs.
    Opdam MAA; Broeder ND; van den Bemt BJF; Mulder K; van de Wiel KM; van Ballegooijen H; van Crevel R; den Broeder AA
    Clin Rheumatol; 2024 Jun; 43(6):2133-2138. PubMed ID: 38703283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK inhibitors in dermatology: The promise of a new drug class.
    Damsky W; King BA
    J Am Acad Dermatol; 2017 Apr; 76(4):736-744. PubMed ID: 28139263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of different Janus kinase inhibitors as monotherapy in rheumatoid arthritis: A Bayesian network meta-analysis.
    Qu B; Zhao F; Song Y; Zhao J; Yao Y; Chen Y; Liao R; Fu L
    PLoS One; 2024; 19(6):e0305621. PubMed ID: 38905267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study.
    Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Onishi A; Jinno S; Hara R; Son Y; Amuro H; Takeuchi T; Yoshikawa A; Katayama M; Yamamoto K; Okita Y; Hirao M; Etani Y; Kumanogoh A; Okada S; Nakata K
    Sci Rep; 2022 Jan; 12(1):134. PubMed ID: 34997059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A meta-analysis of therapeutic trials of topical ruxolitinib cream for the treatment of vitiligo: therapeutic efficacy, safety, and implications for therapeutic practice.
    Hussein AFA; Shams AS; Hosny N; Elrosasy A; Kobtan M; Shafik YA; Alnatsheh ZR; Zeid MA; Qarma M; Ibrahim YK; Al-Sultany HA
    Arch Dermatol Res; 2024 Aug; 316(8):518. PubMed ID: 39134884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical Assessment of Pharmacokinetic Drug-Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment.
    Veeravalli V; Dash RP; Thomas JA; Babu RJ; Madgula LMV; Srinivas NR
    Drug Saf; 2020 Aug; 43(8):711-725. PubMed ID: 32367507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Janus kinase inhibitors in dermatology: A systematic review.
    Shreberk-Hassidim R; Ramot Y; Zlotogorski A
    J Am Acad Dermatol; 2017 Apr; 76(4):745-753.e19. PubMed ID: 28169015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature.
    Samadi A; Ahmad Nasrollahi S; Hashemi A; Nassiri Kashani M; Firooz A
    J Dermatolog Treat; 2017 Sep; 28(6):476-483. PubMed ID: 28024126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK inhibitors in the treatment of adult patients with juvenile idiopathic arthritis: a retrospective monocentric experience.
    Chighizola CB; Pellico MR; Pandolfi M; Marelli L; Cornalba M; Pontikaki I; Costi S; Gattinara M; Marino A; Miserocchi E; Caporali R
    Clin Exp Rheumatol; 2024 May; 42(5):974-982. PubMed ID: 38530666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of Janus Kinase inhibitor selectivity.
    Choy EH
    Rheumatology (Oxford); 2019 Jun; 58(6):953-962. PubMed ID: 30508136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK inhibitors impair GM-CSF-mediated signaling in innate immune cells.
    Fujita Y; Matsuoka N; Temmoku J; Furuya-Yashiro M; Asano T; Sato S; Matsumoto H; Watanabe H; Kozuru H; Yatsuhashi H; Kawakami A; Migita K
    BMC Immunol; 2020 Jun; 21(1):35. PubMed ID: 32539713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK inhibitors in refractory juvenile rheumatic diseases: Efficacy, tolerance and type-I interferon profiling, a single center retrospective study.
    Solignac M; Cabrera N; Fouillet-Desjonqueres M; Duquesne A; Laurent A; Foray AP; Viel S; Zekre F; Belot A
    J Autoimmun; 2024 Jul; 147():103248. PubMed ID: 38797048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.